N/A N=3,617 Randomized Single-blind Treatment

AdaptResponse Clinical Trial

Heart Failure With Left Bundle Branch Block

Bottom Line

View on ClinicalTrials.gov: NCT02205359 ↗

Enrolled (actual)

3,617

Serious AEs

59.3%

Results posted

Nov 2023

Primary outcome: Primary: Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation — 430; 470 Participants — p=0.077

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: aCRT ON (Device); aCRT OFF (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Medtronic Cardiac Rhythm and Heart Failure
Primary completion: Nov 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation	430; 470	0.077
SECONDARY All-cause Mortality	293; 327	0.12
SECONDARY Percent of Patients With Interventions for Heart Failure Decompensation	238; 255	0.28
SECONDARY Clinical Composite Score	1250; 1291; 422; 387; 138; 129	0.11
SECONDARY Atrial Fibrillation	317; 316	0.89
SECONDARY Change in Quality of Life Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)	80.3; 81.8; 16.8; 16.5	0.88
SECONDARY Change in Quality of Life Measured by the EQ-5D	0.848; 0.862; 0.054; 0.048	0.75
SECONDARY All-cause Re-admissions Within 30 Days After a Heart Failure Admission Per 100 Patient Years	1.07; 0.93	0.52

Summary

The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Eligibility Criteria

Inclusion Criteria

Subject is willing to sign and date the study Patient Informed Consent Form.
Subject is indicated for a CRT device according to local guidelines.
Sinus Rhythm at time of enrollment
Complete Left Bundle Branch Block (LBBB) as documented on an ECG (within 30 days prior to enrollment). Strauss Criteria used for LBBB.
Intrinsic, normal AV conduction as documented on an ECG by a PR interval less than or equal to 200ms (within 30 days prior to enrollment).
Left ventricular ejection fraction less than or equal to 35% (documented within 180 days prior to enrollment).
NYHA class II, III or IV (documented within 30 days prior to enrollment) despite optimal medical therapy. Optimal medical therapy is defined as maximal tolerated dose of Beta-blockers and a therapeutic dose of ACE-I, ARB or Aldosterone Antagonist.

Exclusion Criteria

Subject is less than 18 years of age (or has not reached minimum age per local law).
Subject is not expected to remain available for at least 2 years of follow-up visits.
Subject has permanent atrial arrhythmias for which pharmacological therapy and/or cardioversion have been unsuccessful or have not been attempted
Subject is, or previously has been, receiving cardiac resynchronization therapy.
Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.
Subject has unstable angina, or experienced an acute myocardial infarction (MI) or received coronary artery revascularization (CABG) or coronary angioplasty (PTCA) within 30 days prior to enrollment.
Subject has a mechanical tricuspid heart valve or is scheduled to undergo valve repair or valve replacement during the course of the study.
Subject is post heart transplant (subjects on the heart transplant list for the first time are not excluded).
Subject has a limited life expectancy due to non-cardiac causes that would not allow completion of the study.
Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to device implant).
Subject meets any exclusion criteria required by local law.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02205359). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.